VFI provides suitable adjuvants on an open access basis for the preclinical and clinical development of COVID-19 vaccines.
VFI also provides its pandemic formulation platform to support vaccine researchers and developers by testing key adjuvants and formulation parameters to optimize COVID-19 vaccine candidates.
VFI also conducts immunogenicity studies to rapidly evaluate of B and T cell responses in vivo after immunization with adjuvanted COVID-19 vaccine candidates.
The first COVID-19 vaccine containing VFI’s SWE adjuvant is now in clinical trials
COVAC-2, the COVID-19 vaccine developed by VIDO (the Vaccine and infectious Disease Organization at the University of Saskatchewan, Canada) includes the open-access adjuvant Sepivac SWETM, co-developed by VFI and Seppic.